Shanghai Pharmaceuticals Holding Co., Ltd (HKG: 2607)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 71.79B |
| Revenue (ttm) | 301.73B |
| Net Income (ttm) | 4.46B |
| Shares Out | n/a |
| EPS (ttm) | 1.20 |
| PE Ratio | 16.10 |
| Forward PE | n/a |
| Dividend | 0.53 (4.28%) |
| Ex-Dividend Date | Sep 17, 2024 |
| Volume | 2,752,627 |
| Average Volume | 2,482,008 |
| Open | 12.48 |
| Previous Close | 12.42 |
| Day's Range | 12.32 - 12.50 |
| 52-Week Range | 10.04 - 14.70 |
| Beta | 0.32 |
| RSI | 47.88 |
| Earnings Date | Apr 30, 2025 |
About Shanghai Pharmaceuticals Holding
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, syste... [Read more]
Financial Performance
In 2023, Shanghai Pharmaceuticals Holding's revenue was 260.30 billion, an increase of 12.21% compared to the previous year's 231.98 billion. Earnings were 3.77 billion, a decrease of -32.92%.
Financial numbers in CNY Financial StatementsNews
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million ...